Indivior Pharmaceuticals Inc Forecast, price target & analysts
Indivior Pharmaceuticals Inc Target price 2026 - Analyst rating & recommendation
Indivior Pharmaceuticals Inc Classifications & Recommendation
Indivior Pharmaceuticals Inc Price Target
| Target Price | $51.00 |
| Price | $35.71 |
| Potential |
42.82%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Indivior Pharmaceuticals Inc 2027 .
The average Indivior Pharmaceuticals Inc target price is $51.00.
This is
42.82%
register free of charge
$55.65
55.84%
register free of charge
$43.43
21.62%
register free of charge
|
|
| A rating was issued by 10 analysts: 9 Analysts recommend Indivior Pharmaceuticals Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Indivior Pharmaceuticals Inc stock has an average upside potential 2027 of
42.82%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 1.24 | 1.36 |
| 4.29% | 9.85% | |
| EBITDA Margin | 25.34% | 54.22% |
| 3.82% | 113.94% | |
| Net Margin | 16.95% | 38.99% |
| 9,967.80% | 130.04% |
6 Analysts have issued a sales forecast Indivior Pharmaceuticals Inc 2026 . The average Indivior Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Indivior Pharmaceuticals Inc EBITDA forecast 2026. The average Indivior Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Indivior Pharmaceuticals Inc Analysts have issued a net profit forecast 2026. The average Indivior Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.64 | 4.50 |
| 8,100.00% | 174.39% | |
| P/E | 7.94 | |
| EV/Sales | 3.29 |
6 Analysts have issued a Indivior Pharmaceuticals Inc forecast for earnings per share. The average Indivior Pharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
Indivior Pharmaceuticals Inc...
Current Indivior Pharmaceuticals Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Aug 05 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Jun 18 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 12 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 05 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Jun 18 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 12 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
